SomaLogic

SomaLogic, Inc. is a commercial-stage proteomics company, which built an integrated proteomics platform for robust, high throughput proteomics analysis, research and clinical applications. The company was founded by Larry Gold in 2000 and is headquartered in Boulder, CO.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

SomaLogic reports mixed Q4 results, eyes growth through innovation

SomaLogic navigated a mixed financial performance in Q4 2022, focusing on cost management.
The company is strengthening its position in the life sciences sector with innovative products.
Challenges lie in leadership transitions and balancing expenses with growth investments.
Opportunities abound in strategic collaborations, product launches, and market expansion.

SomaLogic reports Q1 revenue growth amid margin challenges

SomaLogic's Q1 performance reflects revenue growth initiatives amidst financial challenges.
Strategic partnerships, expansion plans, and product launches position the company for future growth.
Addressing margin issues and optimizing expenses are critical for achieving profitability and meeting revenue targets.

SomaLogic reports robust Q2 revenue growth, eyes international partnerships

SomaLogic's Q2 2023 performance reflects strong revenue growth and improved cost management, yet challenges persist in achieving profitability.
Strategic strengths include experienced leadership, international expansion, and partnerships driving growth opportunities in the life sciences sector.
Maintaining operational rigor, enhancing margins, and leveraging cash reserves position SomaLogic for sustainable growth and market leadership.

SomaLogic reports revenue growth and strategic merger for future growth

SomaLogic's Q3 2023 performance showed revenue growth and cost management improvements, with a strong cash position. Strategic partnerships and merger offer growth opportunities.
Challenges include revenue decline on a GAAP basis and ongoing EBITDA losses. Opportunities lie in new indications, geographic expansion, and biopharma performance drivers.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BOULDER, Colo., Oct. 31, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that it will report financial results for the third quarter 2023 after market close on November 8, 2023. Management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

SomaLogic to Announce Third Quarter 2023 Financial Results on November 8, 2023

It is merging with a peer in the next-generation medical tech field. This will be effected entirely in stock.

Why SomaLogic Stock Dived by 10% on Wednesday

Standard BioTools Inc

NEW YORK , Oct. 4, 2023 /PRNewswire/ -- Shareholder rights law firm Julie & Holleman LLP is investigating potential breaches of fiduciary duty relating to the proposed merger between Standard BioTools Inc. (Nasdaq: LAB) and SomaLogic, Inc. (Nasdaq: SLGC). For a no-cost consult and to learn more about our investigation, please click here or visit: https://julieholleman.com/?p=3147 Standard BioTools, previously known as Fluidigm Corporation, is a company that develops, manufactures, and sells technologies that help biomedical researchers develop medicines faster and better.

LAB INVESTOR ALERT: Julie & Holleman LLP Announces Investigation of Proposed Merger Between Standard BioTools and SomaLogic

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of SomaLogic, Inc. (NASDAQ: SLGC) to Standard BioTools Inc. for 1.11 shares of Standard BioTools common stock for each share of SomaLogic common stock is fair to SomaLogic shareholders. Halper Sadeh encourages SomaLogic shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalp.

SLGC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of SomaLogic, Inc. Is Fair to Shareholders

MILWAUKEE , Oct. 4, 2023 /PRNewswire/ -- Ademi LLP is investigating SomaLogic (Nasdaq: SLGC) for possible breaches of fiduciary duty and other violations of law in its transaction with Standard BioTools. Click here to learn how to join the action https://www.ademilaw.com/case/somalogic-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether SomaLogic, Inc. has obtained a Fair Price in its transaction with Standard BioTools

SomaLogic Inc.'s SLGC, -2.54% stock was up about 12% in premarket trades on Wednesday after the Boulder, Colo.-based specialist in cell proteins agreed to be acquired in an all-stock merger with Standard BioTools LAB, -1.10% valued at about $1 billion.

SomaLogic's stock surges as it agrees to be bought by Standard BioTools in all-stock merger

Beam Therapeutics

Recursion Pharmaceuticals

Beam Therapeutics is pioneering a promising type of gene editing. Recursion Pharmaceuticals is harnessing AI to improve drug discovery.

3 Stocks Cathie Wood Is Buying That Should Be on Your List, Too

DNA Link will bring the power of the largest proteomics platform available to their biomarker discovery and drug development work DNA Link will bring the power of the largest proteomics platform available to their biomarker discovery and drug development work

SomaLogic and Korea's DNA Link partner to bring the 7,000-plex SomaScan® platform to the fast-growing Asia-Pacific proteomics market

SomaLogic's SomaScan® platform was used to target 15 markers shared among all cancer types. SomaLogic's SomaScan® platform was used to target 15 markers shared among all cancer types.

SomaLogic researchers identify key proteins to aid in early detection of lung, colon and breast cancer and ovarian tumors

Novo Nordisk will extend its use of SomaLogic's innovative proteomics technologies for research in cardiometabolic and other diseases Novo Nordisk will extend its use of SomaLogic's innovative proteomics technologies for research in cardiometabolic and other diseases

SomaLogic expands agreement with Novo Nordisk to 2025

SomaLogic makes life sciences tools. The company said it plans a launch of its SomaScan assay this year.

Why Shares of SomaLogic Are Up Tuesday

Somalogic, Inc. (NASDAQ:SLGC ) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Marissa Bych - Group Investor Relations Adam Taich - Interim CEO Eliot Lurier - Interim CFO Conference Call Participants Kyle Mikson - Canaccord Genuity Daniel Brennan - TD Cowen Daniel Arias - Stifel, Nicolaus & Company Brandon Couillard - Jefferies Operator Good afternoon, and welcome to SomaLogic's Second Quarter 2023 Earnings Conference Call. [Operator Instructions].

Somalogic, Inc. (SLGC) Q2 2023 Earnings Call Transcript

BOULDER, Colo., Aug. 14, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today reported financial results for the quarter ended June 30, 2023.

SomaLogic Reports Second Quarter 2023 Financial Results

BOULDER, Colo., July 24, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that it will report financial results for the second quarter 2023 after market close on August 14th, 2023. Management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

SomaLogic to Announce Second Quarter 2023 Financial Results on August 14, 2023

SomaLogic's 7,000-plex SomaScan® Platform will be used in proteomics testing at scale in Europe. BOULDER, Colo.

SomaLogic partners with Dante Genomics to enhance clinical and research adoption of proteomics in Europe

SkyQuest's Nanomaterials market report provides actionable insights for individuals interested in valuable data, trends, and opportunities in a rapidly growing industry. Additionally, the report is produced and published concisely, making it accessible to various audiences, from industry experts to market readers. Finally, one can gain an in-depth understanding of the primary and secondary market drivers, providing them with a comprehensive outlook of the current market situation and future projections. SkyQuest's Nanomaterials market report provides actionable insights for individuals interested in valuable data, trends, and opportunities in a rapidly growing industry. Additionally, the report is produced and published concisely, making it accessible to various audiences, from industry experts to market readers. Finally, one can gain an in-depth understanding of the primary and secondary market drivers, providing them with a comprehensive outlook of the current market situation and future projections.

Nanomaterials: The future of healthcare and electronics

SomaLogic's 7,000-plex SomaScan® Platform will be used in clinical research, population health studies and nutrigenomics. SomaLogic's 7,000-plex SomaScan® Platform will be used in clinical research, population health studies and nutrigenomics.

SomaLogic Partners with Citogen to Expand Authorized Site Program in Europe

SomaLogic, Inc. (SLGC) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, SLGC's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.

SomaLogic, Inc. (SLGC) Just Flashed Golden Cross Signal: Do You Buy?

Appoints Eliot M. Lurier, CPA, as Interim Chief Financial Officer Reaffirms 2023 Financial Guidance BOULDER, Colo.

SomaLogic Announces Chief Financial Officer Transition

BOULDER, Colo., May 24, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that the company will be participating in the upcoming Jefferies Healthcare Conference.

SomaLogic to Participate in the Jefferies Healthcare Conference

SomaLogic, Inc. (NASDAQ:SLGC ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Marissa Bych - Investor Relations, Gilmartin Group LLC Adam Taich - Chief Executive Officer Shaun Blakeman - Chief Financial Officer Conference Call Participants Daniel Brennan - TD Cowen Dan Arias - Stifel Financial Corp. Kyle Mikson - Canaccord Genuity Group Inc. Brandon Couillard - Jefferies Group LLC Operator Good afternoon, and welcome to SomaLogic's First Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.

SomaLogic, Inc. (SLGC) Q1 2023 Earnings Call Transcript

SomaLogic, Inc. (SLGC) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.15 per share a year ago.

SomaLogic, Inc. (SLGC) Reports Q1 Loss, Tops Revenue Estimates

SomaLogic to deliver 7,000-plex SomaScan® Platform to researchers in attractive Chinese proteomics market SomaLogic to deliver 7,000-plex SomaScan® Platform to researchers in attractive Chinese proteomics market

SomaLogic expands into China with groundbreaking Biostar Technology Limited Partnership

Two winners will be awarded 40 human plasma or serum samples to be processed on the SomaScan ® Platform at Genomax's Singapore lab

SomaLogic opens their first-ever proteomics grant program to APAC life sciences researchers

SAN DIEGO--(BUSINESS WIRE)---- $SLGC #CorvexManagement--SomaLogic, Inc.

News for SomaLogic Stock (SLGC)